{"id":740249,"date":"2023-03-15T08:34:35","date_gmt":"2023-03-15T12:34:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/"},"modified":"2023-03-15T08:34:35","modified_gmt":"2023-03-15T12:34:35","slug":"onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/","title":{"rendered":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWTOWN, Pa., March  15, 2023  (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023.<\/p>\n<p align=\"justify\">The full texts of the published abstracts can be found on the AACR Annual Meeting website. The corresponding posters will be presented during the \u201cCyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors\u201d poster session, which is taking place from 9:00 a.m. \u2013 12:30 p.m. ET on April 19, 2023. Additional information on the posters is shown below.<\/p>\n<p align=\"justify\">\n        <strong>Poster Title: <\/strong>Synergistic activity of the CDK4\/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma<\/p>\n<p align=\"justify\">\n        <strong>Abstract Number:<\/strong> 5974<\/p>\n<p align=\"justify\">This poster will describe studies evaluating narazaciclib in preclinical models of mantle cell lymphoma (MCL). Results from these studies demonstrated narazaciclib\u2019s single-agent antitumor activity in MCL cell lines independent of their sensitivity to ibrutinib, which is a Bruton\u2019s tyrosine kinase inhibitor (BTKi) approved by the U.S. Food and Drug Administration (FDA) for the treatment of MCL. When combining narazaciclib with ibrutinib, synergistic increases in antitumor activity against both BTKi-resistant and BTKi-sensitive MCL cell lines were observed.<\/p>\n<p align=\"justify\">Additional analyses showed that narazaciclib\u2019s antitumor activity against the evaluated MCL cell lines was superior to that of the FDA-approved CDK 4\/6 inhibitors palbociclib and ribociclib, and similar to that of the FDA-approved CDK 4\/6 inhibitor abemaciclib. Treatment with narazaciclib also led to tumor growth inhibition without detectable toxicity in a chicken embryo chorioallantoic membrane (CAM) xenograft model of MCL.<\/p>\n<p align=\"justify\">\n        <strong>Poster Title: <\/strong>Differential targets engaged by narazaciclib in comparison to the approved CDK4\/6 inhibitors contribute to enhanced inhibition of tumor cell growth<\/p>\n<p align=\"justify\">\n        <strong>Abstract Number:<\/strong> 5987<\/p>\n<p align=\"justify\">This poster will describe cell-based, <em>in vitro,<\/em> and bioinformatic analyses comparing narazaciclib and palbociclib. Results from a cell-based murine mammary carcinoma model showed a stronger induction of programmed cell death with narazaciclib compared to palbociclib. <em>In vitro <\/em>and cell-based analyses revealed multiple targets that are engaged by narazaciclib but not by palbociclib. These targets included BUB1, the overexpression of which is correlated with poor survival in triple negative breast cancer. The results of additional cell-based assays that will be described in the poster suggest that narazaciclib may promote antitumor immunity and show that combining narazaciclib with autophagy inhibitors sensitizes breast cancer cells to cell death.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About Onconova Therapeutics, Inc. <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.<\/p>\n<p align=\"justify\">Onconova\u2019s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose escalation and expansion studies. These trials are currently underway in the United States and China. Based on preclinical and clinical studies of CDK 4\/6 inhibitors, Onconova is also planning a combination trial of narazaciclib with estrogen blockade in advanced endometrial cancer, as well as its clinical study in additional indications.<\/p>\n<p align=\"justify\">Onconova\u2019s product candidate rigosertib is being studied in multiple investigator-sponsored studies, including a dose-escalation and expansion Phase 1\/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, and a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=opMigYiu114ds-viDDildz3I86ZxGX9Bk723aaqjShHQcD9zffW60-UVpeoMcW95SrgbUvBG05MVq8Y13LpiCw==\" rel=\"nofollow noopener\" target=\"_blank\">www.onconova.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Forward-Looking Statements<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova\u2019s expectations regarding its clinical development and trials, its product candidates, its business and financial position. Onconova has attempted to identify forward-looking statements by terminology including &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; \u201cpreliminary,\u201d \u201cencouraging,\u201d &#8220;approximately&#8221; or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova&#8217;s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova\u2019s collaborations, market conditions and those discussed under the heading &#8220;Risk Factors&#8221; in Onconova&#8217;s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Mark Guerin<br \/>Onconova Therapeutics, Inc.<br \/>267-759-3680<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DVSOdDaTuNVtR7IJ_ot0euC0vLkoj7qiuoJLk_OaMpgh6sZ_1uNL2_OYAQiLXsjM9opbdsaSKKqlbgBQ5D_JVg==\" rel=\"nofollow noopener\" target=\"_blank\">ir@onconova.us<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ukxMTewDmoN2uslA3pNlDjz4bzh-B1youB2NWfX0VZnuXSar4xzgVrK8gbSwAr0CZTw67q_E22VWmxhO0W85oVNbUWL4n9QY8FdGqCD0n5xYPBC7yfqppOxSfVo1IUqH\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.onconova.com\/contact\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Bruce Mackle <br \/>LifeSci Advisors, LLC<br \/>646-889-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eALKILxMgcmqbKGFl7EAV9Bjd9OvXN7-8GM9zbPju7XrKsNI1SkmT_lcxwv-OCwxDxT2pVx3ngtxfjufm6sifVPerI6Eul7NRvb0v-AMmezLqPz0hV8MLxhKGe3jvqH1\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NWM1MTY0NzYtNTZkNy00YjU1LTliMzgtZDFkYjFiZDY3OTIyLTEwMTcxODg=\/tiny\/Onconova-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full texts of the published abstracts can be found on the AACR Annual Meeting website. The corresponding posters will be presented during the \u201cCyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors\u201d poster session, which is taking place from 9:00 a.m. \u2013 12:30 p.m. ET on April 19, 2023. Additional &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740249","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full texts of the published abstracts can be found on the AACR Annual Meeting website. The corresponding posters will be presented during the \u201cCyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors\u201d poster session, which is taking place from 9:00 a.m. \u2013 12:30 p.m. ET on April 19, 2023. Additional &hellip; Continue reading &quot;Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T12:34:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting\",\"datePublished\":\"2023-03-15T12:34:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/\"},\"wordCount\":862,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/\",\"name\":\"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\",\"datePublished\":\"2023-03-15T12:34:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk","og_description":"NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), (\u201cOnconova\u201d), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full texts of the published abstracts can be found on the AACR Annual Meeting website. The corresponding posters will be presented during the \u201cCyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors\u201d poster session, which is taking place from 9:00 a.m. \u2013 12:30 p.m. ET on April 19, 2023. Additional &hellip; Continue reading \"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-15T12:34:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting","datePublished":"2023-03-15T12:34:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/"},"wordCount":862,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/","name":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=","datePublished":"2023-03-15T12:34:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODUzMyM1NDYyNzA0IzIwMDU2MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-announces-upcoming-poster-presentations-at-the-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740249"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}